Source: Atherosclerosis. Conference titles: Congress of the European Atherosclerosis Society. Unidade: FM
Subjects: MUTAÇÃO GENÉTICA, HIPERCOLESTEROLEMIA, CORONARIOPATIA (PREVENÇÃO E CONTROLE)
ABNT
CAVALI, S. et al. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 24 maio 2024. , 2004APA
Cavali, S., Moretti, I., Matsumoto, L., Salazar, L., Hiroyuki, M., Forti, N. A., et al. (2004). Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo.NLM
Cavali S, Moretti I, Matsumoto L, Salazar L, Hiroyuki M, Forti NA, Diament J, Chiara M, Faludi A, Dominguez R. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. 2004 ; 5( 1): 112.[citado 2024 maio 24 ]Vancouver
Cavali S, Moretti I, Matsumoto L, Salazar L, Hiroyuki M, Forti NA, Diament J, Chiara M, Faludi A, Dominguez R. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. 2004 ; 5( 1): 112.[citado 2024 maio 24 ]